Propranolol for infantile haemangioma: Striking effect in the first weeks

Katona, Gábor; Csákányi, Zsuzsanna; Gács, E; Szalai, Zsuzsanna; Ráth, Gábor; Gerlinger, Imre

doi:10.1016/j.ijporl.2012.08.014

Cited by 19 publications

(11 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…17,18 The recurrence of hemangiomas after propranolol seems to be inversely correlated with age and the duration of treatment. 19,20 In our series none of the patients were younger than 2 months, and we administered propranolol to patients for at least 6 months in all cases, which could explain the absence of recurrence. Siegfried et al 21 reported a ''ladder'' treatment protocol to optimize safety: Medication is given every 8 hours, with an initial dose of 0.16 mg/kg of body weight.…”

Section: Discussionmentioning

confidence: 73%

Treatment of Severe Infantile Hemangiomas With Propranolol: An Evaluation of the Efficacy and Effects of Cardiovascular Parameters in 25 Consecutive Patients

Cao

Xue

et al. 2015

Journal of Oral and Maxillofacial Surgery

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 73%

Treatment of Severe Infantile Hemangiomas With Propranolol: An Evaluation of the Efficacy and Effects of Cardiovascular Parameters in 25 Consecutive Patients

Cao

Xue

et al. 2015

Journal of Oral and Maxillofacial Surgery

View full text Add to dashboard Cite

“…[25] Ever since there has been a series of publications describing its therapeutic efficacy and side effects. [262728293031323334353637383940] Currently, it is widely used in IH, particularly for complicated and ulcerated IH, and appears to be the best therapeutic modality. [31]…”

Section: Introductionmentioning

confidence: 99%

Management of infantile hemangiomas: Current trends

Sethuraman

Yenamandra

Gupta

2014

J Cutan Aesthet Surg

View full text Add to dashboard Cite

Infantile hemangiomas (IH) are common vascular tumours. IH have a characteristic natural course. They proliferate rapidly during the early infantile period followed by a period of gradual regression over several years. Most of the uncomplicated IH undergo spontaneous involution, with a small proportion of cases requiring intervention. These are children with IH in life-threatening locations, local complications like haemorrhage, ulceration and necrosis and functional or cosmetic disfigurements. Systemic corticosteroids have been the first line of treatment for many years. Recently, non-selective beta-blockers, such as oral propranalol and topical timolol, have emerged as promising and safer therapies. Other treatment options include interferon α and vincristine which are reserved for life-threatening haemangiomas that are unresponsive to conventional therapy. This review mainly focuses on the current trends and evidence-based approach in the management of IH.

show abstract

“…Although different authors tried high doses of propranolol (4.5 mg/kg/day) it seems that dosage does not affect the rate of therapeutic efficiency regarding hemangiomas 39 and low doses (1-1.5 mg/kg/day) are efficacious; lesions which do not show an initial response to the lower dose are unlikely to respond to the higher dose quantity of 3-4 mg/kg/day, so non-responsive patients to the treatment remain. 34 In infantile hemangiomas, after initial regression, the later improvement is much slower, sometimes with periods of stagnation, and they recommend treatment should be continued for at least six months because early cessation can cause a relapse, 34,41 which we found in the patients that discontinued treatment. The maximum dosages of propranolol should be adjusted individually to each patient depending on the response and tolerability, but depending on the affection in which it is used the following doses have demonstrated to be safe: 640 mg/day in hypertension, 480mg/day in angina, 240 mg/day in migraine and tachycardia, 160mg/day in arrhythmias, hyperthyroidism and hypertrophic obstructive cardiomyopathy, and up to 160mg/12 hours in upper gastrointestinal bleeding.…”

Section: Discussionmentioning

confidence: 78%

Oral Propranolol in Von Hippel Lindau Ocular Affection

González-Rodríguez

Ramírez

et al. 2020

Preprint

View full text Add to dashboard Cite

Background. von Hippel Lindau (VHL) disease is a familial syndrome associated with benign and malignant tumours. These tumours appear in the retina, among other locations. The retinal hemangioblastomas are one of the earliest and most frequent manifestations of this entity, and they can lead to blindness at a young age. Propranolol could be a promising treatment for retinal hemangioblastomas in von Hippel Lindau disease Methods. Prospective cohort study of seven patients with VHL disease and ocular affection that had rejected conventional treatment, taking oral propranolol. We evaluated them for three years, with a complete ophthalmic evaluation that included: visual acuity, intraocular pressure, an examination of the anterior segment of the eye, fundoscopy, retinography, and optical coherence tomography (OCT). Heart rate and blood pressure were also measured. During the follow-up evaluation, two patients discontinued the treatment with propranolol after the first year and rejected any further treatment for their ocular affection; the rest continued therapy. Results. Visual acuity and tumour areas remained stable in 4 patients. Increased and new retinal exudation area was found in the two patients that discontinued the treatment with oral propranolol. Conclusions. Oral propranolol has shown a role in the reabsorption of retinal exudates in patients with VHL affection. It could delay or stabilise the ocular disease, maintaining visual acuity and avoiding further complications in these patients. It is a well-known and available drug, without so many secondary effects, that could also have a role in other ocular diseases that course with exudation. Trial registration. VHL-HOPE-2014-1. EudraCT Number: 2014-003671-30; Registered 22 September 2014 - https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003671-30/ES

show abstract

Propranolol for infantile haemangioma: Striking effect in the first weeks

Cited by 19 publications

References 16 publications

Treatment of Severe Infantile Hemangiomas With Propranolol: An Evaluation of the Efficacy and Effects of Cardiovascular Parameters in 25 Consecutive Patients

Treatment of Severe Infantile Hemangiomas With Propranolol: An Evaluation of the Efficacy and Effects of Cardiovascular Parameters in 25 Consecutive Patients

Management of infantile hemangiomas: Current trends

Oral Propranolol in Von Hippel Lindau Ocular Affection

Contact Info

Product

Resources

About